mynth
← DATABASE
12/2021MajorityLBO

Vivalto Partners, IK Partners, Macsf, Arkea Capital & BNP Paribas Developpement take majority stake in Vivalto Santé

FRANCE Health Providers / Healthcare Facilities / Clinics / Hospitals EV €1–10bn

Context

Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo. The transaction is notably characterised by a strong medical and employee shareholder component, with approximately 1,000 physicians and ultimately 35% of employees targeted as co-investors. The financing structure comprises a Term Loan B and a revolving credit facility, supplemented by subordinated instruments arranged by Hayfin.

As a reminder, Vivalto Santé had previously acquired Mathilde Médical Développement in 2020 as part of its expansion strategy.

Vivalto Santé, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (14.8x in 2021).

-> Deep-dive in Healthcare & Pharma market trends

Target

Vivalto Santé is a leading French private hospital and clinic group, founded in 2009 by Daniel Caille and a group of physicians, operating under a distinctive "third way" governance model that associates medical professionals and financial investors under a shared ownership and decision-making structure. The group has grown rapidly through an active acquisition strategy.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2021
€1–10bn
€100–200M
[members only]
2020
€1–10bn
€100–200M
[members only]

Other operations with Vivalto Santé

Other operations with Vivalto Santé
DateAcquirerTargetCountrySector
01/2020VIVALTO SANTÉMATHILDE MÉDICAL DÉVELOPPEMENTFRANCEClinics / Hospitals

Similar deals in Health Providers

Similar deals in Health Providers
DateAcquirerTargetCountrySector
02/2022PARTNERS GROUPFOREFRONT DERMATOLOGYUNITED STATESOutpatient Care
01/2022WREN HOUSEVOYAGE CAREUNITED KINGDOMNursing Homes
12/2021RAMSAY HEALTH CAREELYSIUM HEALTHCAREUNITED KINGDOMClinics / Hospitals
11/2021CERBA HEALTHCARELABEXAFRANCELabs (Biology)
10/2021IVC EVIDENSIAVETONEFRANCEVet Clinics
10/2021ARES / BPIFRANCEPOINT VISIONFRANCEOphthalmology
10/2021THE CRANEMERE GROUPOUTPATIENT IMAGING AFFILIATESUNITED STATESRadiology
09/2021LIVINGBRIDGEEVERLIGHT RADIOLOGYUNITED KINGDOMRadiology
08/2021COLOSSEUM DENTAL GROUPCURAEOSNETHERLANDSDental Centers
07/2021CERBA HEALTHCARELIFEBRAINITALYLabs (Biology)

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €1–10bn

EBITDA range: €100–200M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Vivalto Santé by Vivalto Partners / IK Partners / Macsf / Arkea Capital / BNP Paribas Developpement are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: vivalto santé

Acquirer: vivalto partners / ik partners / bnp paribas developpement / macsf / arkea capital

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Vivalto Santé, a French company specialised in Healthcare Facilities, by Vivalto Partners, IK Partners, Macsf, Arkea Capital and BNP Paribas Developpement in 2021, structured as a leveraged buyout (LBO).

How was the acquisition of Vivalto Santé by Vivalto Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Vivalto Santé’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Vivalto Santé generated annual revenue estimated in the €1–10bn range and EBITDA in the €100–200M bracket (FY 2021). Detailed financial figures are available to members.

How does the valuation of Vivalto Santé compare to benchmarks in the Healthcare & Pharma sector?

With an estimated multiple range of 10x - 18x, the transaction stands directly in line with historical averages for the Healthcare & Pharma sector (14.8x in 2021).

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.